We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.14% | 35.45 | 35.20 | 35.60 | 35.65 | 35.20 | 35.45 | 246,675 | 16:35:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.14 | 105.85M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/10/2022 15:08 | freddie why did you compare Futura to Enron? LOL freddievas - 27 Sep 2021 - 14:15:44 - 9974 of 13655 Enron was worth North of $60billion....a bit of a way to go yet! freddievas - 08 May 2019 - 12:03:56 - 5324 of 13655 pump and dump I fear. freddievas - 21 Mar 2018 - 10:07:21 - 3982 of 13656 "Futura a winner for 2015" says it all really. | lbo | |
12/10/2022 14:12 | Should have known better. Filtered anyway. | freddievas | |
12/10/2022 12:50 | Hey Broomrigg how come you are not posting your more buyers then sellers posts today? Whats that other important stock market saying. Its better to travel then arrive. Could that be the case with the realisation its just a De Novo medical device application! LOL FOR EVERY BUYER THERE MUST BE A SELLER Jay: What I meant was, where did the shares you purchased come from? They didn’t come out of thin air. Someone had to sell them to you. The market has two types of investors: individuals like you and me, and institutional investors such as pension funds, mutual funds and hedge funds. Do you believe the seller was more likely another individual investor like you? Or was the seller more likely one of those institutional investors? Haden: I would guess the seller was another individual investor. Jay: That’s incorrect. Since today institutional investors do about 90 percent of all trading, there’s about a 90 percent chance the seller was an institution. Since we now agree the underlying reason you bought the stock was that you believed it would outperform the market, we can also agree the underlying reason the institutional investor sold the stock was that it believed the stock would underperform the market. If that were not the case, it would have continued to hold the stock. Correct? Haden: I guess so. Jay: Okay. You believed it would outperform the market, and the institutional investor believed it would underperform. How many of you can be correct? Haden: Just one. Jay: If you’re being perfectly honest with yourself, who do you believe had more knowledge about the company—you or the institutional investor? Haden: I’d have to say the institutional investor. | lbo | |
12/10/2022 11:15 | How ironic mike you now talk of ‘misguided intent’! So where was the ˜initial upfront payment’ from Cooper in the results!? LOL mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141 Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141 Company is massively over valued if you go by 'concrete' results ! mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141 I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections. I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 ! mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591 "A couple of decent deals and will be back off to the races." Do you have any idea of how long shareholders have been using these words mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591 As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated. All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day! mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713 why should it be any different this time when you've still got the same useless lot running the show mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641 I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick | lbo | |
12/10/2022 10:59 | No he was ever only an avatar of an obsession with misguided intent | mikethebike4 | |
12/10/2022 10:37 | Gosh, I wonder if LBO is still alive! | freddievas | |
07/10/2022 16:10 | Fair point. | joestalin | |
07/10/2022 16:10 | Fair point. | joestalin | |
07/10/2022 09:03 | Joe I am also worried about your and Dontshoutatonce mental health! You seem to have forgotten what you used to say about Futura and we know dontshoutatonce is seriously down on his shares Dontshoutatonce - 04 Jun 2018 - 17:36:54 - 4248 of 13648 Sleeping is the word but no beauty. I've been with FUM for about 10 years or more and it's not worth my selling as I'm down a big % JoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774 FUTURA a winner for 2015 - says it all! JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775 'jam tomorrow' is a very easy promise to make. JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775 What's another year after all? At FUM, time is measured in decades. JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775 There seems to be an unlimited number of ways of saying "Jam tomorrow". JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775 A lifestyle company, but not for the shareholders. | lbo | |
06/10/2022 19:48 | All Futura have done is also allow Reckitt to sell lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that Med3000 itself has no proven effect in ED beyond a placebo. As it has not proven efficacy in a placebo controlled study or even against any standard cooling lubricant/arousal gels. ‘You are the active ingredient’ Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly. KEY GROWTH FACTORS Increasing prevalence of erectile dysfunction 9 Market Growth Enablers 9.1 Increasing Prevalence of Erectile Dysfunction For many, whether or not placebo use is ethical depends partly on whether patients are being deceived and whether there is a known better treatment. A clinician who doesn’t deceive a patient, and who provides a placebo for something for which there is no known treatment, such as irritable bowel syndrome, might be ethically OK, says Jeremy Howick, of the Department of Primary Health Care Sciences, at the University of Oxford, and lead author of the Plos One study. “Bu | lbo | |
06/10/2022 19:05 | By the way, it's far too late to be worrying about his mental health - he's been doing this for five years. | petroc | |
06/10/2022 19:04 | I can do that. You'll end up with just his voice dissing our investments though, because he won't stop. He's on a crusade. Petroc out. | petroc | |
06/10/2022 18:31 | Here. Here JoeStalin. Petroc, please ignore LBO. | dontshoutatonce | |
06/10/2022 18:08 | If you keep engaging with him, you will encourage him. Best to filter him. For his own mental health as much as anything. | joestalin | |
06/10/2022 13:25 | More buyers than sellers again today :-) | broomrigg | |
06/10/2022 10:29 | Never mind the flannel, LiarBO, let's see your evidence that MED3000 doesn't work. | petroc | |
06/10/2022 09:08 | The burden of proof is on you to substantiate your claims! The FTC, ASA or others ‘will not seek out the evidence to establish the veracity of the claim for you’ petroc - 09 Jan 2022 - 16:44:16 - 10345 of 10423 Of course it works petroc22 Jan '22 - 19:08 - 10569 of 10768 What is not to love Eroxon /MED3000 - HERE ARE THE FACTS It is the advertisers s responsibility to hold evidence for the claims they make, and it is stipulated in the Advertising Codes that evidence must be held by the advertiser prior to making the claim. Advertisers must submit documentary evidence to the ASA to support any claims they make; the ASA will not seek out the evidence to establish the veracity of the claim for you. When submitting evidence for new or breakthrough claims, sound data, relevant to the advertised claim(s), should be collated to form a body of evidence. The totality of this evidence is important; marketers should not ignore sound data that does not support the new claim, especially where current opinion is divided. Where evidence is limited to very few studies, the studies should have robust results to ensure the basis for the claim is sound | lbo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions